Wells Fargo has recently raised Ventyx Biosciences Inc (VTYX) stock to Overweight rating, as announced on March 12, 2024, according to Finviz. Earlier, on March 12, 2024, Oppenheimer had raised the stock from a Perform to Outperform, setting a price target of $12. Wells Fargo also reduced Equal Weight rating with a price target of $8. Additionally, Stifel reduced Hold rating on November 7, 2023, with a target price of $6. Oppenheimer analysts, in their report published on November 7, 2023, also reduced Perform rating for Ventyx Biosciences Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Ventyx Biosciences Inc (VTYX) Stock Trading Recap
On Monday, Ventyx Biosciences Inc (VTYX) stock saw a decline, ending the day at $2.18 which represents a decrease of $-0.13 or -5.63% from the prior close of $2.31. The stock opened at $2.31 and touched a low of $2.15 during the day, reaching a high of $2.34. The volume of shares traded was 1.14 million falling short of the average volume of 1.29 million.
VTYX Stock Performance and Moving Averages
In recent trading, Ventyx Biosciences Inc (VTYX) stock price has shown some volatility, fluctuating -11.38% over the last five trades and -0.91% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -61.00%, and it has plunged by -3.54% in the previous three months. Currently, VTYX is trading at -3.99%, -2.96%, and -39.07% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, VTYX, a Healthcare sector stock, is trading -93.98% below its 52-week high but remains 21.79% above its 52-week low. The Average True Range (ATR) (14 days) of 0.17 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Ventyx Biosciences Inc’s Profitability and Valuation Ratios
Ventyx Biosciences Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -61.00%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Ventyx Biosciences Inc’s market capitalization stands at $154.06 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Book Ratio is 0.55, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 22.62% of Ventyx Biosciences Inc (VTYX)’s shares, while financial institutions hold 71.59%.
Notable insider trades include Mohan Raju, CEO and President at Ventyx Biosciences Inc (VTYX), who sold 58860 shares on Dec 20 ’23, at $2.12 each, totaling $0.12 million. On Oct 09 ’23, NSV Partners III LP, 10% Owner, sold 49152 shares for $30.03 each, amounting to $1.48 million. Additionally, on Oct 09 ’23, Subramaniam Somu sold 49152 shares at $30.03 each, generating $1.48 million.
